NTSR1 Antibody

What is NTSR1 and why is it important in research?

NTSR1 is a G-protein coupled receptor for the tridecapeptide neurotensin (NTS). In humans, it has an amino acid length of 418 and an expected molecular mass of 46.3 kDa. NTSR1 is also known by alternative names including NTR, neurotensin receptor type 1, and NT-R-1. This receptor commonly expresses in the central nervous system, particularly in brain regions such as the hypothalamus and basal ganglia, as well as in peripheral tissues like the gastrointestinal tract . NTSR1 plays significant roles in neurotransmission, neuromodulation, and has been implicated in several pathological conditions, most notably in cancer progression. Recent studies have demonstrated its involvement in gastric cancer progression through activation of signaling pathways that promote cell migration, invasion, and matrix metalloproteinase expression . The multifaceted functions of NTSR1 make it an important target for both basic research and therapeutic development.

What applications are NTSR1 antibodies validated for?

NTSR1 antibodies are validated for various experimental applications, with different products optimized for specific techniques. Based on commercial offerings, commonly supported applications include:

• Western Blot (WB): For detecting denatured NTSR1 protein in cell/tissue lysates

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement of NTSR1 levels

• Immunocytochemistry (ICC)/Immunofluorescence (IF): For visualizing NTSR1 localization in cultured cells

• Immunohistochemistry on paraffin sections (IHC-P): For detecting NTSR1 in fixed tissue samples

• Flow Cytometry (FCM): For analyzing NTSR1 expression in cell populations

Some antibodies show broader application compatibility than others. For example, certain antibodies are validated for multiple techniques (WB, IF, IHC), while others might be optimized for specific applications . Researchers should select antibodies validated for their intended application and conduct preliminary validation experiments to confirm performance in their specific experimental system.

How should I validate the specificity of an NTSR1 antibody?

Validating antibody specificity is essential for reliable experimental results. A comprehensive validation approach should include:

• Genetic knockdown/knockout controls:

  • Transfect cells with NTSR1-targeting siRNAs as described in published protocols using sequences such as: si1 (sense: CGUAGGUAGGGACACGUGU[dTdT], antisense: ACACGUGUCCCUACCUACG[dTdT]); si2 (sense: CUCAGACUAAUGGAUGGUU[dTdT], antisense: AACCAUCCAUUAGUCUGAG[dTdT]); or si3 (sense: GAGUUGACGGGUUCCUUGA[dTdT], antisense: UCAAGGAACCCGUCAACUC[dTdT])

  • Compare antibody signal in control versus knockdown samples

  • A specific antibody will show significantly reduced signal in knockdown cells

• Positive and negative tissue controls:

  • Test antibody on tissues known to express NTSR1 (brain regions like hypothalamus) versus those with minimal expression

  • Compare antibody labeling with mRNA expression data from in situ hybridization or RNA-seq databases

• Multiple antibody approach:

  • Use antibodies targeting different epitopes of NTSR1

  • Consistent labeling patterns across different antibodies suggest specificity

It's worth noting that commercial antibodies sometimes fail to provide labeling consistent with mRNA distribution patterns, as reported for brain tissue . In such cases, alternative approaches like genetic reporter systems may be necessary.

What protocol is recommended for immunofluorescence detection of NTSR1?

For optimal immunofluorescence detection of NTSR1, the following protocol has been successfully employed in research:

• Fixation:

  • Fix cells in 4% formaldehyde for 20 minutes at room temperature

• Blocking and permeabilization:

  • Block nonspecific binding with Abdil solution (0.1% Triton X-100 and 2% bovine serum albumin) for 30 minutes

• Antibody incubation:

  • Incubate with anti-NTSR1 antibody in blocking buffer overnight at 4°C

  • Wash thoroughly with Tris-buffered saline (3-5 washes, 5 minutes each)

  • Incubate with appropriate secondary antibodies in blocking buffer for 2 hours at room temperature

  • Counterstain nuclei with 4′,6-diamidino-2-phenylindole (DAPI)

• Imaging:

  • Mount coverslips using appropriate mounting medium

  • Image using confocal laser-scanning microscopy (40× magnification is typically sufficient for cellular localization studies)

For membrane proteins like NTSR1, permeabilization conditions require careful optimization. Excessive permeabilization may disrupt membrane structure and epitope integrity, while insufficient permeabilization might prevent antibody access to intracellular epitopes. When studying cellular localization, co-staining with markers for specific subcellular compartments can provide additional context for interpretation.

How can siRNA be used to validate NTSR1 antibody specificity in functional studies?

siRNA-mediated knockdown provides a powerful approach for validating NTSR1 antibody specificity in functional studies. A validated protocol includes:

• siRNA selection and preparation:

  • Use validated siRNA sequences targeting different regions of NTSR1 mRNA

  • Include non-targeting control siRNA with similar GC content

  • Prepare siRNA according to manufacturer's instructions

• Transfection protocol:

  • Culture cells in six-well plates until reaching optimal confluence (typically 70-80%)

  • Transfect with NTSR1 siRNAs or control siRNA using Lipofectamine 2000 reagent following manufacturer guidelines

  • After 6 hours incubation at 37°C, add 1 ml of complete medium containing serum

  • Allow 48-72 hours for efficient knockdown

• Validation of knockdown efficiency:

  • Extract RNA and perform qRT-PCR to quantify NTSR1 mRNA reduction

  • Prepare protein lysates and perform Western blot using the NTSR1 antibody to confirm protein reduction

  • Document knockdown efficiency for proper interpretation of functional results

• Functional assays:

  • Perform parallel functional experiments using control and NTSR1 knockdown cells

  • Include antibody-based detection to correlate function with receptor expression

  • Analyze whether antibody-detected functions are abolished or reduced in knockdown cells

This approach not only validates antibody specificity but also confirms that observed functional effects are specifically attributable to NTSR1 rather than off-target effects of the antibody or experimental manipulations.

How can NTSR1 antibodies be utilized to investigate cancer progression?

NTSR1 antibodies have become valuable tools for investigating cancer progression, particularly in gastric cancer research. Multiple experimental approaches demonstrate their utility:

• Expression profiling in clinical samples:

  • Immunohistochemical analysis of NTSR1 in tumor tissue microarrays

  • Comparison of expression between tumor and adjacent normal tissue

  • Correlation with clinicopathological features and patient outcomes

  • Research has shown significantly higher NTSR1 mRNA levels in gastric cancer tissues compared to non-cancerous tissues

• Investigation of signaling mechanisms:

  • Western blot analysis to detect NTSR1 expression across cancer cell lines

  • Study of downstream effectors following neurotensin (NT) treatment

  • Research has demonstrated that NT treatment induces matrix metalloproteinase-9 (MMP-9) expression and activity in gastric cancer cells

  • Comparison of signaling in cells with normal versus knocked-down NTSR1 expression

• Cell migration and invasion studies:

  • Wound-healing assays to assess cell migration following NT treatment

  • Transwell invasion assays using Matrigel-coated chambers

  • Quantification of invasive capacity in the presence or absence of NTSR1 inhibition

  • Implementation of control experiments using NTSR1 siRNA to confirm receptor involvement

• Development of targeted therapies:

  • Screening for compounds that modulate NTSR1 activity or expression

  • Evaluation of antibody-drug conjugates targeting NTSR1-expressing cancer cells

  • Assessment of combination therapies targeting NTSR1 alongside standard treatments

These applications collectively support the potential of NTSR1 as both a biomarker and therapeutic target in various cancers, building upon findings that plasma NT levels are significantly elevated in cancer patients .

What approaches can be used to study NTSR1 receptor internalization and trafficking?

NTSR1, like many GPCRs, undergoes dynamic internalization and trafficking upon ligand binding. Several methodological approaches can investigate these processes:

• Time-course immunofluorescence studies:

  • Treat cells with NT for defined time intervals (5, 15, 30, 60 minutes)

  • Fix cells and perform immunofluorescence using NTSR1 antibodies

  • Co-stain with markers for endosomal compartments (Rab5 for early endosomes, Rab7 for late endosomes, LAMP1 for lysosomes)

  • Quantify receptor redistribution from membrane to intracellular compartments over time

• Surface biotinylation assays:

  • Biotinylate cell surface proteins using membrane-impermeable biotinylation reagents

  • Treat cells with NT for various durations

  • Isolate remaining biotinylated (surface) proteins using streptavidin pulldown

  • Detect NTSR1 by Western blot to quantify internalization rates

• Flow cytometry for receptor downregulation:

  • Label non-permeabilized cells with NTSR1 antibodies to detect surface expression

  • Compare untreated versus NT-treated cells at various time points

  • Quantify the decrease in surface receptor levels following ligand exposure

• Recycling analysis:

  • Block protein synthesis with cycloheximide

  • Induce receptor internalization with NT treatment

  • Remove NT and monitor receptor return to the cell surface over time

  • Use NTSR1 antibodies to quantify the recycling component versus degradation

These approaches provide complementary information about the spatiotemporal dynamics of NTSR1 trafficking and can reveal how these processes might be altered in pathological conditions like cancer.

Why might NTSR1 antibodies show inconsistent labeling patterns in brain tissue?

Researchers have reported challenges with commercial NTSR1 antibodies in brain tissue, noting that they "did not yield labeling consistent with the ISH distribution of NTSR1 and NTSR2 in mouse brain" . Several technical factors may contribute to this inconsistency:

• Epitope accessibility issues:

  • Complex brain tissue architecture and high lipid content can mask epitopes

  • Different fixation protocols affect epitope preservation differently

  • Various antigen retrieval methods (heat-induced versus enzymatic) may be required

  • Optimization of detergent concentration and permeabilization time is often necessary

• Expression level considerations:

  • NTSR1 may be expressed at levels below detection threshold in certain regions

  • Signal amplification methods (tyramide signal amplification, polymer detection systems) may be required

  • Alternative high-sensitivity techniques like RNAscope for mRNA detection can provide complementary data

• Post-translational modifications:

  • Region-specific receptor modifications may alter antibody binding

  • Different receptor conformations or protein-protein interactions might mask epitopes

  • Multiple antibodies targeting different regions of NTSR1 can help address this issue

• Specificity challenges:

  • Cross-reactivity with similar proteins (particularly NTSR2)

  • Non-specific binding to abundant brain proteins

  • Background signal from endogenous peroxidases or biotin

To overcome these challenges, researchers have developed alternative approaches such as the dual recombinase knock-in mouse models that allow genetic labeling of NTSR1-expressing cells . These genetic approaches can provide more reliable identification when antibody-based detection proves challenging.

How can I distinguish between NTSR1 and NTSR2 in tissues where both receptors are expressed?

Distinguishing between the highly related neurotensin receptors NTSR1 and NTSR2 requires careful experimental design:

• Antibody selection strategy:

  • Choose antibodies raised against divergent regions of NTSR1 and NTSR2 sequences

  • Validate specificity using cells expressing only one receptor subtype (through overexpression or selective knockdown)

  • Consider monoclonal antibodies with demonstrated specificity for subtype-specific epitopes

• Genetic validation approaches:

  • Use receptor-specific siRNA knockdown to validate antibody specificity

  • The knock-in mouse models described in research can provide specific labeling of either NTSR1 or NTSR2 expressing cells

  • Comparison with receptor knockout tissues offers definitive validation

• Pharmacological discrimination:

  • Use subtype-selective agonists and antagonists

  • Compare functional responses between receptor subtypes

  • Combine with antibody detection to confirm receptor identity

• Dual labeling approaches:

  • Perform sequential or simultaneous immunostaining with antibodies against both receptors

  • Use antibodies raised in different host species to allow simultaneous detection

  • Analyze co-localization patterns to identify cells expressing one or both receptors

• Complementary RNA detection:

  • Use in situ hybridization with subtype-specific probes

  • Compare with antibody labeling patterns

  • RNAscope or similar high-sensitivity techniques allow simultaneous detection of multiple receptor transcripts

These approaches can be combined to provide a more comprehensive and reliable distinction between these closely related receptor subtypes.

What genetic approaches are being developed to study NTSR1-expressing cells?

Recent advances in genetic tools have revolutionized the study of NTSR1-expressing cells, addressing limitations of traditional antibody-based approaches:

• Dual recombinase knock-in mouse models:

  • Innovative systems where FlpO expression is required to induce IRES-Cre in cells expressing NTSR1

  • Cre-mediated recombination then induces reporter proteins (e.g., GFP) specifically in these cells

  • This approach provides temporal control over recombination by inducing FlpO at defined developmental timepoints

• Development process:

  • NEO-Cre targeting vectors inserted IRES-Cre between the stop codon and polyadenylation site of the mouse NTSR1 gene

  • The linearized vector was electroporated into mouse embryonic stem cells

  • Resulting mouse lines enable precise genetic access to NTSR1-expressing cells

• Developmental analysis capabilities:

  • Embryonic model: FlpO expression during embryogenesis labels cells expressing NTSR1 during development

  • Adult model: FlpO adenovirus injection in adulthood labels cells currently expressing NTSR1

  • This allows studying developmental trajectories of NTSR1-expressing populations

• Cellular characterization:

  • GFP-labeled NTSR1-expressing cells can be characterized using immunohistochemistry

  • Co-staining with markers like NeuN (neurons), S100β (glia), and TH (dopaminergic neurons) identifies specific cell populations

  • This approach has revealed cellular mechanisms by which neurotensin can directly engage NTSR1-expressing dopaminergic neurons to modify dopamine signaling

These genetic approaches complement traditional antibody-based methods and provide unprecedented specificity for studying NTSR1 biology in complex tissues like the brain.

How does NTSR1 contribute to cancer progression and what are the therapeutic implications?

Research using NTSR1 antibodies has revealed important mechanisms by which this receptor contributes to cancer progression:

• Signaling mechanisms:

  • NTSR1 activation by neurotensin triggers multiple signaling cascades

  • Matrix metalloproteinase-9 (MMP-9) expression and activity increases following receptor activation

  • This promotes degradation of extracellular matrix components, facilitating cancer cell invasion

• Cellular effects:

  • Enhanced cell migration in wound-healing assays following neurotensin treatment

  • Increased invasion through Matrigel in transwell assays

  • These effects can be blocked by NTSR1 siRNA knockdown, confirming receptor specificity

• Clinical correlations:

  • NTSR1 mRNA levels are significantly higher in gastric cancer tissues compared to non-cancerous tissues

  • Plasma neurotensin levels are elevated in cancer patients

  • Expression levels may correlate with tumor progression and poor prognosis

• Therapeutic potential:

  • NTSR1 represents a promising target for cancer therapy

  • Strategies include receptor antagonists, antibody-drug conjugates, and RNA interference

  • Studies suggest that NTSR1 could serve as "a new specific and effective therapeutic target" particularly in gastric cancer

• Diagnostic applications:

  • Combined analysis of NTSR1 expression and plasma neurotensin levels

  • Potential biomarker for early detection and monitoring treatment response

  • Development of imaging probes targeting NTSR1 for cancer visualization

These findings collectively support NTSR1 as both a biomarker and therapeutic target, with ongoing research focused on translating these insights into clinical applications.